Menago

Irbesartan, the active ingredient in Menago, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetic nephropathy in adult patients.

GNH USA supplies Menago as a licensed, GDP‑compliant international pharmaceutical product, adhering to European Union manufacturing standards. The company provides the medication to hospitals, pharmacies and clinics worldwide, supporting consistent quality, regulatory compliance and reliable supply chains for cardiovascular care.

Irbesartan is used to treat conditions related to the renin‑angiotensin system and to protect renal function. - Hypertension: lowers elevated blood pressure, reducing the risk of cardiovascular events. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Left ventricular hypertrophy: helps reduce the risk of stroke in hypertensive patients with cardiac remodeling.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate cranial pain. - Hyperkalemia: elevated blood potassium levels. - Abdominal pain: discomfort in the stomach area. - Cough: occasional dry throat irritation.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue or throat. - Severe hyperkalemia: dangerously high potassium that may affect heart rhythm. - Acute renal failure: sudden loss of kidney function. - Hepatic injury: liver enzyme elevations or hepatitis. - Neutropenia: marked reduction in white blood cells. - Anaphylaxis: life‑threatening allergic reaction.

Before initiating Irbesartan therapy, consider the following precautions. - Blood pressure monitoring: regularly check to ensure therapeutic control. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte surveillance: monitor potassium levels, especially with concomitant potassium‑sparing agents. - Hypersensitivity: avoid in patients with known ARB allergy. - Pregnancy and lactation: contraindicated in the second and third trimesters; consult a specialist. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan can interact with several medicines; awareness of the interaction level is essential.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): combined use may increase renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: risk of severe hyperkalemia. - ACE inhibitors: concurrent use can lead to additive hypotension and renal impairment.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - NSAIDs: can reduce renal clearance of irbesartan and raise potassium. - CYP3A4 inhibitors (e.g., ketoconazole): may increase irbesartan plasma concentrations. - Rifampin: may lower irbesartan levels, reducing efficacy. - Lithium: increased lithium concentrations, risking toxicity.